TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Healios KK ( (JP:4593) ).
Healios K.K. has appointed D.J. Skelton as an advisor to assist in advancing its global drug development activities, particularly in the United States. Skelton’s military background and personal experience with ARDS are expected to enhance Healios’ strategic engagements with the U.S. government and medical facilities involved in clinical trials for MultiStem, aiming to secure vital approvals and partnerships.
More about Healios KK
Healios K.K. operates in the biotechnology industry, focusing on the development of regenerative medicines, particularly somatic stem cell and iPSC regenerative medicines. Its primary product, MultiStem, is designed for conditions such as acute respiratory distress syndrome (ARDS), ischemic stroke, and trauma, with a market focus on global territories following regulatory designations for expedited approval.
YTD Price Performance: 0%
Average Trading Volume: 1,009,345
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen15.95B
Learn more about 4593 stock on TipRanks’ Stock Analysis page.